Selected research
Market Structure
Global Montelukast Intermediate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Montelukast Intermediate market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Montelukast Intermediate include VIVAN Life Sciences, P.G. Shah & Co., Ortin Laboratories and Manus Aktteva Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Montelukast Intermediate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Montelukast Intermediate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Montelukast Intermediate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Montelukast Intermediate market size, projected growth trends, production technologies, key applications, and end-use industries.
Montelukast Intermediate Segment by Company
VIVAN Life Sciences
P.G. Shah & Co.
Ortin Laboratories
Manus Aktteva Biopharma
Montelukast Intermediate Segment by Type
GMP
Non-GMP
Montelukast Intermediate Segment by Application
Bronchospasm
Urticaria
Asthma
Allergic Rhinitis
Montelukast Intermediate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Montelukast Intermediate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Montelukast Intermediate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Montelukast Intermediate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Montelukast Intermediate market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Montelukast Intermediate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Montelukast Intermediate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Montelukast Intermediate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- GMP
- Non-GMP
Applications
- Bronchospasm
- Urticaria
- Asthma
- Allergic Rhinitis
Companies covered
- VIVAN Life Sciences
- P.G. Shah & Co.
- Ortin Laboratories
- Manus Aktteva Biopharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Montelukast Intermediate Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Montelukast Intermediate Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Montelukast Intermediate Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Montelukast Intermediate Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Montelukast Intermediate Market Dynamics
- 2.1 Montelukast Intermediate Industry Trends
- 2.2 Montelukast Intermediate Industry Drivers
- 2.3 Montelukast Intermediate Industry Opportunities and Challenges
- 2.4 Montelukast Intermediate Industry Restraints
3 Montelukast Intermediate Market by Manufacturers
- 3.1 Global Montelukast Intermediate Revenue by Manufacturers (2021-2026)
- 3.2 Global Montelukast Intermediate Sales by Manufacturers (2021-2026)
- 3.3 Global Montelukast Intermediate Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Montelukast Intermediate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Montelukast Intermediate Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Montelukast Intermediate Manufacturers, Product Type & Application
- 3.7 Global Montelukast Intermediate Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Montelukast Intermediate Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Montelukast Intermediate Players Market Share by Revenue in 2025
- 3.8.3 2025 Montelukast Intermediate Tier 1, Tier 2, and Tier 3
4 Montelukast Intermediate Market by Type
- 4.1 Montelukast Intermediate Type Introduction
- 4.1.1 GMP
- 4.1.2 Non-GMP
- 4.2 Global Montelukast Intermediate Sales by Type
- 4.2.1 Global Montelukast Intermediate Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Montelukast Intermediate Sales by Type (2021-2032)
- 4.2.3 Global Montelukast Intermediate Sales Market Share by Type (2021-2032)
- 4.3 Global Montelukast Intermediate Revenue by Type
- 4.3.1 Global Montelukast Intermediate Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Montelukast Intermediate Revenue by Type (2021-2032)
- 4.3.3 Global Montelukast Intermediate Revenue Market Share by Type (2021-2032)
5 Montelukast Intermediate Market by Application
- 5.1 Montelukast Intermediate Application Introduction
- 5.1.1 Bronchospasm
- 5.1.2 Urticaria
- 5.1.3 Asthma
- 5.1.4 Allergic Rhinitis
- 5.2 Global Montelukast Intermediate Sales by Application
- 5.2.1 Global Montelukast Intermediate Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Montelukast Intermediate Sales by Application (2021-2032)
- 5.2.3 Global Montelukast Intermediate Sales Market Share by Application (2021-2032)
- 5.3 Global Montelukast Intermediate Revenue by Application
- 5.3.1 Global Montelukast Intermediate Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Montelukast Intermediate Revenue by Application (2021-2032)
- 5.3.3 Global Montelukast Intermediate Revenue Market Share by Application (2021-2032)
6 Global Montelukast Intermediate Sales by Region
- 6.1 Global Montelukast Intermediate Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Montelukast Intermediate Sales by Region (2021-2032)
- 6.2.1 Global Montelukast Intermediate Sales by Region (2021-2026)
- 6.2.2 Global Montelukast Intermediate Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Montelukast Intermediate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Montelukast Intermediate Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Montelukast Intermediate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Montelukast Intermediate Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Montelukast Intermediate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Montelukast Intermediate Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Montelukast Intermediate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Montelukast Intermediate Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Montelukast Intermediate Revenue by Region
- 7.1 Global Montelukast Intermediate Revenue by Region
- 7.1.1 Global Montelukast Intermediate Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Montelukast Intermediate Revenue by Region (2021-2026)
- 7.1.3 Global Montelukast Intermediate Revenue by Region (2027-2032)
- 7.1.4 Global Montelukast Intermediate Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Montelukast Intermediate Revenue (2021-2032)
- 7.2.2 North America Montelukast Intermediate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Montelukast Intermediate Revenue (2021-2032)
- 7.3.2 Europe Montelukast Intermediate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Montelukast Intermediate Revenue (2021-2032)
- 7.4.2 Asia-Pacific Montelukast Intermediate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Montelukast Intermediate Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Montelukast Intermediate Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 VIVAN Life Sciences
- 8.1.1 VIVAN Life Sciences Company Information
- 8.1.2 VIVAN Life Sciences Business Overview
- 8.1.3 VIVAN Life Sciences Montelukast Intermediate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 VIVAN Life Sciences Montelukast Intermediate Product Portfolio
- 8.1.5 VIVAN Life Sciences Recent Developments
- 8.2 P.G. Shah & Co.
- 8.2.1 P.G. Shah & Co. Company Information
- 8.2.2 P.G. Shah & Co. Business Overview
- 8.2.3 P.G. Shah & Co. Montelukast Intermediate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 P.G. Shah & Co. Montelukast Intermediate Product Portfolio
- 8.2.5 P.G. Shah & Co. Recent Developments
- 8.3 Ortin Laboratories
- 8.3.1 Ortin Laboratories Company Information
- 8.3.2 Ortin Laboratories Business Overview
- 8.3.3 Ortin Laboratories Montelukast Intermediate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Ortin Laboratories Montelukast Intermediate Product Portfolio
- 8.3.5 Ortin Laboratories Recent Developments
- 8.4 Manus Aktteva Biopharma
- 8.4.1 Manus Aktteva Biopharma Company Information
- 8.4.2 Manus Aktteva Biopharma Business Overview
- 8.4.3 Manus Aktteva Biopharma Montelukast Intermediate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Manus Aktteva Biopharma Montelukast Intermediate Product Portfolio
- 8.4.5 Manus Aktteva Biopharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Montelukast Intermediate Value Chain Analysis
- 9.1.1 Montelukast Intermediate Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Montelukast Intermediate Production Mode & Process
- 9.2 Montelukast Intermediate Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Montelukast Intermediate Distributors
- 9.2.3 Montelukast Intermediate Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst